Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 2013 | Accepted Version + Supplemental Material
Journal Article Open

Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element

Abstract

Pyrrole-imidazole (Py–Im) polyamides are a class of programmable DNA minor groove binders capable of modulating the activity of DNA-binding proteins and affecting changes in gene expression. Estrogen receptor alpha (ERα) is a ligand-activated hormone receptor that binds as a homodimer to estrogen response elements (ERE) and is a driving oncogene in a majority of breast cancers. We tested a selection of structurally similar Py–Im polyamides with differing DNA sequence specificity for activity against 17β-estadiol (E2)–induced transcription and cytotoxicity in ERα positive, E2-stimulated T47DKBluc cells, which express luciferase under ERα control. The most active polyamide targeted the sequence 5′-WGGWCW-3′ (W = A or T), which is the canonical ERE half site. Whole transcriptome analysis using RNA-Seq revealed that treatment of E2-stimulated breast cancer cells with this polyamide reduced the effects of E2 on the majority of those most strongly affected by E2 but had much less effect on the majority of E2-induced transcripts. In vivo, this polyamide circulated at detectable levels following subcutaneous injection and reduced levels of ER-driven luciferase expression in xenografted tumors in mice after subcutaneous compound administration without significant host toxicity.

Additional Information

© 2013 American Association for Cancer Research. Received October 29, 2012; revised February 8, 2013; accepted February 15, 2013; published Online First February 26, 2013. The authors thank Drs. Janet Baer, Dr. Karen L. Lencioni, and Gwen E. Williams for helpful discussions and technical assistance with animal experiments. Sequencing was conducted at the Millard and Muriel Jacobs Genetics and Genomics Laboratory at California Institute of Technology. This work was supported in large part by the NIH Grant GM-51747. N.G. Nickols received support from the Jonsson Cancer Center Foundation at UCLA. J.O. Szablowski and B.C. Li were supported by NIH GM-51747. J.A. Raskatov received postdoctoral support from the Alexander von Humboldt foundation. A.E. Hargrove received postdoctoral support from the California Tobacco-Related Disease Research Program (19FT-0105) and the NIH (NRSA number 1F32CA156833). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. N.G. Nickols and J.O. Szablowski contributed equally to this work. Authors' Contributions: Conception and design: N.G. Nickols, J.O. Szablowski, J.A. Raskatov, P.B. Dervan Development of methodology: N.G. Nickols, J.O. Szablowski, B.C. Li, P.B. Dervan Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): N.G. Nickols, J.O. Szablowski, A.E. Hargrove, B.C. Li Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): N.G. Nickols, J.O. Szablowski, A.E. Hargrove, J.A. Raskatov, P.B. Dervan Writing, review, and/or revision of the manuscript: N.G. Nickols, J.O. Szablowski, A.E. Hargrove, B.C. Li, J.A. Raskatov, P.B. Dervan Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): N.G. Nickols, J.O. Szablowski, P.B. Dervan Study supervision: P.B. Dervan No potential conflicts of interest were disclosed.

Attached Files

Accepted Version - nihms449618.pdf

Supplemental Material - Fig_1_PDF_43K.pdf

Supplemental Material - Fig_2_PDF_107K.pdf

Supplemental Material - Fig_3_PDF_16K.pdf

Supplemental Material - Fig_4_PDF_43K.pdf

Supplemental Material - Fig_5_PDF_31K.pdf

Supplemental Material - Fig_6_PDF_24K.pdf

Supplemental Material - Fig_7_PDF_776K.pdf

Supplemental Material - Fig_8_PDF_219K.pdf

Supplemental Material - Fig_and_Tab_legs_PDF_98K.pdf

Supplemental Material - Tab_1_PDF_45K.pdf

Supplemental Material - Tab_2_PDF_31K.pdf

Supplemental Material - Tab_3_PDF_241K.pdf

Files

Fig_4_PDF_43K.pdf
Files (5.1 MB)
Name Size Download all
md5:e16a289619f1f94decd1bcc443264069
34.4 kB Preview Download
md5:8de0fc5d63f51416679190dcf3ad177e
98.6 kB Preview Download
md5:37275894b43ae38a020055b48b0e25d4
26.7 kB Preview Download
md5:4ba41ca4f5b8a93778a8c7ceeec262bd
19.7 kB Preview Download
md5:3e1700e39d6b5f08c2c9e8aea3f23b50
102.6 kB Preview Download
md5:b9d306fbe92c4cfe9234ab46c3f772da
3.6 MB Preview Download
md5:ec478a493871c6631978971ecb5d0e84
17.8 kB Preview Download
md5:3985c67f5c8641cdf1ccf6e5bbe6eb9e
215.7 kB Preview Download
md5:f05e2e662871eaa58e439e890874a59d
205.7 kB Preview Download
md5:e959ef3cf6269a4ecbf432da403308c0
789.6 kB Preview Download
md5:eeeb173228eda511a76a79edaa48ea2c
33.4 kB Preview Download
md5:40b2f49059cce4455e62515833b9f07b
14.2 kB Preview Download
md5:1c2bcc4fc50e16e889f9a982bec8632b
20.2 kB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 24, 2023